The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tabeeva G.R.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Mild cognitive impairment: what’s next?

Authors:

Tabeeva G.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10): 103‑110

DOI: 10.17116/jnevro2019119101103

Read: 13519 times

Download PDF (RU)
Contact the author
Table of contents

MILD COGNITIVE IMPAIRMENT: WHAT’S NEXT?
MILD COGNITIVE IMPAIRMENT: WHAT’S NEXT?

To cite this article:

Tabeeva GR. Mild cognitive impairment: what’s next? S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10):103‑110. (In Russ.)
https://doi.org/10.17116/jnevro2019119101103

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Como­rbidity of depression and deme­ntia: epidemiological, biological and therapeutic aspe­cts. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121
Acti­vation of endo­genous mechanisms of sano­genesis in cognitive impairment in cere­bral small vessel disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):7-13
Cognitive impairment in bili­nguals with neurological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):26-29
The rela­tionship between neuropsychological indi­cators and neuroimaging changes acco­rding to MRI morphometry in patients with Alzheimer’s disease and glaucoma. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):142-152
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
Nutritional care for patients with neurodegenerative diseases in the outpatient practice of a neurologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):76-83
The expe­rience of diagnosing Alzheimer’s disease based on the study of cere­brospinal fluid biomarkers. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):91-97
Neurobiological pote­ntial of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):7-12
Animal expe­rimental models in the study of age-dependent cere­bral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):57-68
Abstract:

The concept of mild cognitive impairment is one of the promising directions for studying the predementia stages of different diseases. The feasibility of studying this phenomenon is due not only to a high risk of dementia, but also the potential reversibility of cognitive decline in old age. Long-term follow-up of patients shows different trajectories of cognitive decline in aging. The study of risk factors for the progression of moderate cognitive impairment provided an opportunity to highlight new horizons of prevention of dementia of various etiologies. Despite the insufficient effectiveness of drug therapy in patients with moderate cognitive impairment, exploring the opportunities for possible treatment of their subtypes seems promising from the point of view of improving clinical symptoms and a possible reduction in the rate of disease progression.

Keywords:

mild cognitive impairment
subjective cognitive decline
dementia
Alzheimer’s disease
vascular dementia
vascular cognitive impairment

Authors:

Tabeeva G.R.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Close metadata

References:

  1. Cheng YW, Chen TF, Chiu MJ. From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution. Neuropsychiatric Disease and Treatment. 2017;13:491-498. eCollection 2017. https://doi.org/10.2147/NDT.S123428
  2. Lo RY. The borderland between normal aging and dementia. Tzu Chi Medical Journal. 2017;29(2):65-71.
  3. Kral VA. Senescent forgetfulness: Benign and malignant. Can Med Assoc J. 1962;86:257-260.
  4. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol. 1999;56:303-308. https://doi.org/10.1001/archneur.56.3.303
  5. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136-1139. https://doi.org/10.1176/ajp.139.9.1136
  6. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194. https://doi.org/10.1111/j.1365-2796.2004.01388.x
  7. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC. Mild cognitive impairment — beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240-246. https://doi.org/10.1111/j.1365-2796.2004.01380.x
  8. Ward A, Arrighi HM, Michels S, Cedarbaum JM. Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimer’s Dement. 2012;8(1):14-21. https://doi.org/10.1016/j.jalz.2011.01.002
  9. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014;275(3):214-228. https://doi.org/10.1111/joim.12190
  10. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the united states (2010—2050) estimated using the 2010 census. Neurology. 2013;80:1778-1783. https://doi.org/10.1212/WNL.0b013e31828726f5
  11. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. Archives of Neurology. 2001;58:1985:1992.
  12. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH. Prevalence and classfication of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60(10):1385-1389.
  13. Wolf H, Grunwald M, Ecke GM, Zedlick D, Bettin S, Dannenberg C, Dietrich J, Eschrich K, Arendt T, Gertz HJ. The prognosis of mild cognitive impairment in the elderly. J Neural Transm Suppl. 1998;54:31-50.
  14. Ingles JL, Fisk JD, Merry HR, Rockwood K. Five-year outcomes for dementia defined solely by neuropsychological test performance. Neuroepidemiol. 2003;22:172-178.
  15. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia — meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119:252-265. https://doi.org/10.1111/j.1600-0447.2008.01326.x
  16. Mitchell A, Shiri-Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J Neurol Neurosurg Psychiatry. 2008;79:1386-1391. https://doi.org/10.1136/jnnp.2007.142679
  17. Ward A, Tardiff S, Dye C, Arrighi HM. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: a systematic review of the literature. Dement Geriatr Cogn Dis Extra. 2013;3(1):320-332. eCollection 2013. https://doi.org/10.1159/000354370
  18. Busse A, Angermeyer MC, Riedel-Heller SG. Progression of mild cognitive impairment to dementia: a challenge to current thinking. Br J Psychiatry. 2006;189:399-404. https://doi.org/10.1192/bjp.bp.105.014779
  19. Serrano CM, Dillon C, Leis A, Taragano FE, Allegri RF. Mild cognitive impairment: risk of dementia according to Subtypes. Actas Esp Psiquiatr. 2013;41(6):330-339.
  20. Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic — vs community-based cohorts. Arch Neurol. 2009;66:1151-1157. https://doi.org/10.1001/archneurol.2009.106
  21. Roberts RO, Knopman DS, Mielke MM, Cha RH, Pankratz VS, Christianson TJH, Geda YE, Boeve BF, Ivnik RJ, Tangalos EG. Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology. 2014;82:317-325. https://doi.org/10.1212/WNL.0000000000000055
  22. Barnes DE, Cenzer IS, Yaffe K, Ritchie CS, Lee SJ. Alzheimer’s Disease Neuroimaging Initiative: a point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer’s disease. Alzheimers Dement. 2014;10:646-655. https://doi.org/10.1016/j.jalz.2013.12.014
  23. Sun Y, Yang FC, Lin CP, Han Y. Biochemical and neuroimaging studies in subjective cognitive decline: progress and perspectives. CNS Neurosci Ther. 2015;21(10):768-775. https://doi.org/10.1111/cns.12395
  24. Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand. 2014;130(6):439-451. https://doi.org/10.1111/acps.12336
  25. Jessen F, Amariglio RE, van Boxtel M. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s Dement. 2014;10(6):844-852. https://doi.org/10.1016/j.jalz.2014.01.001
  26. Slavin MJ, Sachdev PS, Kochan NA, Woolf C, Crawford JD, Giskes K, Reppermund S, Trollor JN, Draper B, Delbaere K, Brodaty H. Predicting cognitive, functional, and diagnostic change over 4 Years using baseline subjective cognitive complaints in the Sydney memory and ageing study. Am J Geriatr Psychiatry. 2015;23(9):906-914. https://doi.org/10.1016/j.jagp.2014.09.001
  27. Caselli RJ, Chen K, Locke DE, Lee W, Roontiva A, Bandy D, Fleisher AS, Reiman EM. Subjective cognitive decline: self and informant comparisons. Alzheimer’s Dement. 2014;10(1):93-98. https://doi.org/10.1016/j.jalz.2013.01.003
  28. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-216. https://doi.org/10.1016/S1474-4422(12)70291-0
  29. Sperling RA, Aisen PS, Beckett La, Bennett D, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimer’s Dement. 2011;7:280-292. https://doi.org/10.1016/j.jalz.2011.03.003
  30. Prince M, Ali G, Guerchet M, Prina AM, Albanese E, Wu Y. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther. 2016;8:23. https://doi.org/10.1186/s13195-016-0188-8
  31. Slot RER, Sikkes SAM, Berkhof J. Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia Alzheimers Dement. 2019;15(3):465-476. https://doi.org/10.1016/j.jalz.2018.10.003
  32. Yaneva-Sirakova T, Tarnovska-Kadreva R, Traykov L 792. Blood pressure variability and mild cognitive impairment. Bulg J Cardiol. 2013;1:5-14.
  33. Gomez-Angelats N, de la Sierra A, Sierra C, Parati G, Mancia G, Coca. Blood pressure variability and silent 796 cerebral damage in essential hypertension. Am J Hypertens. 2004;17:696-700.
  34. Yaneva-Sirakova T, Tarnovska-Kadreva R, Traykov L Atrial fibrillation and mild cognitive impairment. Alzheimer Dement. 2013;9:770-771.
  35. Meguro K, Dodge HH. Vascular Mild Cognitive Impairment: Identifying Disease in Community-Dwelling Older Adults, Reducing Risk Factors, and Providing Support. The Osaki-Tajiri and Kurihara Projects. Journal of Alzheimer’s Disease. 2019;1:1-10. https://doi.org/10.3233/JAD-180899
  36. Solfrizzi V, Scafato E, Capurso C, D’Introno A, Colacicco AM, Frisardi V, Vendemiale G, Baldereschi M, Crepaldi G, Di Carlo A, Galluzzo L, Gandin C, Inzitari D, Maggi S, Capurso A, Panza F. Italian Longitudinal Study on Aging Working Group. Metabolic syndrome, mild cognitive impairment, and progression to dementia. Neurobiol Aging. 2011;32:1932-1941. https://doi.org/10.1016/j.neurobiolaging.2009.12.012
  37. Solfrizzi V, Panza F, Colacicco AM, D’Introno A, Capurso C, Torres F, Grigoletto F, Maggi S, Del Parigi A, Reiman EM, Caselli RJ, Scafato E, Farchi G, Capurso A; Italian Longitudinal Study on Aging Working Group. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology. 2004;63:1882-1891. https://doi.org/10.1212/01.wnl.0000144281.38555.e3
  38. Kryscio RJ, Abner EL, Lin Y, Cooper GE, Fardo DW, Jicha GA, Nelson PT, Smith CD, Van Eldik LJ, Wan L, Schmitt FA. Adjusting for mortality when identifying risk factors for transitions to mild cognitive impairment and dementia. J Alzheimers Dis. 2013;35:823-832. https://doi.org/10.3233/JAD-122146
  39. Solfrizzi V, D’Introno A, Colacicco AM, Capurso C, Del Parigi A, Baldassarre G, Scapicchio P, Scafato E, Amodio M, Capurso A, Panza F; Italian Longitudinal Study on Aging Working Group. Alcohol consumption, mild cognitive impairment, and progression to dementia. Neurology. 2007;68:1790-1799. https://doi.org/10.1212/01.wnl.0000262035.87304.89
  40. Xu G, Liu X, Yin Q, Zhu W, Zhang R, Fan X. Alcohol consumption and transition of mild cognitive impairment to dementia. Psychiatry Clin Neurosci. 2009;63:43-49. https://doi.org/10.1111/j.1440-1819.2008.01904.x
  41. Cooper C, Sommerlad A, Lyketsos CG, Livingston G. Modifiable Predictors of Dementia in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. Am J Psychiatry. 2015;172:323-334. https://doi.org/10.1176/appi.ajp.2014.14070878
  42. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. Arch Neurol. 2009;66:216-225. https://doi.org/10.1001/archneurol.2008.536
  43. Schneider LS, Insel PS, Weiner MW, Alzheimer’s Disease Neuroimaging Initiative. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer’s Disease Neuroimaging Initiative. Arch Neurol. 2011;68:58-66. https://doi.org/10.1001/archneurol.2010.343
  44. Luck T, Riedel-Heller SG, Luppa M, Wiese B, Bachmann C, Jessen F, Bickel H, Weyerer S, Pentzek M, König HH, Prokein J, Eisele M, Wagner M, Mösch E, Werle J, Fuchs A, Brettschneider C, Scherer M, Breitner JC, Maier W. A hierarchy of predictors for dementia-free survival in old-age: results of the AgeCoDe study. Acta Psychiatr Scand. 2014;129:63-72. https://doi.org/10.1111/acps.12129
  45. Paradise M, Cooper C, Livingston G. Systematic review of the effect of education on survival in Alzheimer’s disease. Int Psychogeriatr. 2009;21:25-32. https://doi.org/10.1017/S1041610208008053
  46. Meyer JS, Xu G, Thornby J, Chowdhury MH, Quach 650 M. Is mild cognitive impairment prodromal for 651 vascular dementia like Alzheimer’s disease? Stroke. 2002;33:652:1981-1985.
  47. Makin SD, Turpin S, Dennis MS, Wardlaw JM. Cognitive impairment after lacunar stroke: Systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes. J Neurol Neurosurg Psychiatry. 2013;84:893-900. https://doi.org/10.1136/jnnp-2012-303645
  48. Van Rooij FG, Kessels RP, Richard E, De Leeuw FE, van Dijk EJ. Cognitive impairment in transient ischemic attack patients: A systematic review. Cerebrovasc Dis. 2016;42:9. https://doi.org/10.1159/000444282
  49. Harrison SL, Tang EY, Keage HA, Taylor JP, Allan L, Robinson L, Jagger C, Rockwood K, Stephan BC. A systematic review of the definitions of vascular cognitive impairment, no dementia in Cohort studies. Dement Geriatr Cogn Dis. 2016;42:69-79. https://doi.org/10.1159/000448213
  50. Fink HA, Jutkowitz E, McCarten JR, Hemmy LS, Butler M, Davila H, Ratner E, Calvert C, Barclay TR, Brasure M, Nelson VA, Kane RL. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Ann Intern Med. 2018;168(01):39-51. https://doi.org/10.7326/M17-1529
  51. DeKosky S. Early intervention is key to successful management of Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;4:99-104.
  52. McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J. Memantine for dementia. Cochrane Database Syst Rev. 2019;3:CD003154. https://doi.org/10.1002/14651858.CD003154.pub6
  53. Fedin AI, Belskaya GN, Kurushina OV, Kovalchuk VV, Starych EV, Chichanovskaya LV, Baranova OA. Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study). Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;118(9):35-42. (In Russ.) https://doi.org/10.17116/jnevro201811809135
  54. Fedin AI. The efficacy of cortexin and memantinol (memantine) in the treatment of cognitive impairment in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;118(1):30-36. (In Russ.) https://doi.org/10.17116/jnevro20181181130-36
  55. Fioravanti M, Buckley AE. Citicoline (Cognizin) in the treatment of cognitive impairment. Clin Interv Aging. 2006;1(3):247-251.
  56. Mashin VV, Belova LA, Bakhtogarimov IR, Bergelson TM, Sharafutdinova RR. Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;117(8):39-43. (In Russ.) https://doi.org/10.17116/jnevro20171178139-43
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.